10-12 September 2018 //  Lancaster Royal Hotel, London

Dr Martin Andrews, SVP Rare Diseases, GSK

Strimvelis is the first ex-vivo stem cell gene therapy to treat patients with Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency, or commonly known as 'Bubble Boy Disease'). We caught up with Dr Andrews, who leads GSK's Rare Disease Development team at our Miami Leaders Forum 2017.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad